PMID- 35551616
OWN - NLM
STAT- MEDLINE
DCOM- 20220810
LR  - 20220818
IS  - 2190-3948 (Electronic)
IS  - 2190-393X (Print)
IS  - 2190-393X (Linking)
VI  - 12
IP  - 9
DP  - 2022 Sep
TI  - Physiologically based pharmacokinetic modeling of intravenously administered 
      nanoformulated substances.
PG  - 2132-2144
LID - 10.1007/s13346-022-01159-w [doi]
AB  - The use of nanobiomaterials (NBMs) is becoming increasingly popular in the field 
      of medicine. To improve the understanding on the biodistribution of NBMs, the 
      present study aimed to implement and parametrize a physiologically based 
      pharmacokinetic (PBPK) model. This model was used to describe the biodistribution 
      of two NBMs after intravenous administration in rats, namely, poly(alkyl 
      cyanoacrylate) (PACA) loaded with cabazitaxel (PACA-Cbz), and LipImage 815. A 
      Bayesian parameter estimation approach was applied to parametrize the PBPK model 
      using the biodistribution data. Parametrization was performed for two distinct 
      dose groups of PACA-Cbz. Furthermore, parametrizations were performed three 
      distinct dose groups of LipImage 815, resulting in a total of five different 
      parametrizations. The results of this study indicate that the PBPK model can be 
      adequately parametrized using biodistribution data. The PBPK parameters estimated 
      for PACA-Cbz, specifically the vascular permeability, the partition coefficient, 
      and the renal clearance rate, substantially differed from those of LipImage 815. 
      This emphasizes the presence of kinetic differences between the different 
      formulations and substances and the need of tailoring the parametrization of PBPK 
      models to the NBMs of interest. The kinetic parameters estimated in this study 
      may help to establish a foundation for a more comprehensive database on 
      NBM-specific kinetic information, which is a first, necessary step towards 
      predictive biodistribution modeling. This effort should be supported by the 
      development of robust in vitro methods to quantify kinetic parameters.
CI  - (c) 2022. The Author(s).
FAU - Minnema, Jordi
AU  - Minnema J
AUID- ORCID: 0000-0002-1847-4218
AD  - National Institute for Public Health and the Environment, Bilthoven, The 
      Netherlands. jordi.minnema@rivm.nl.
FAU - Borgos, Sven Even F
AU  - Borgos SEF
AD  - SINTEF, Trondheim, Norway.
FAU - Liptrott, Neill
AU  - Liptrott N
AD  - Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute 
      of Systems, Molecular and Integrative Biology, University of Liverpool, 
      Liverpool, UK.
FAU - Vandebriel, Rob
AU  - Vandebriel R
AD  - National Institute for Public Health and the Environment, Bilthoven, The 
      Netherlands.
FAU - Delmaar, Christiaan
AU  - Delmaar C
AD  - National Institute for Public Health and the Environment, Bilthoven, The 
      Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220512
PL  - United States
TA  - Drug Deliv Transl Res
JT  - Drug delivery and translational research
JID - 101540061
SB  - IM
MH  - Animals
MH  - Bayes Theorem
MH  - Kinetics
MH  - Metabolic Clearance Rate
MH  - *Models, Biological
MH  - Rats
MH  - Tissue Distribution
PMC - PMC9360077
OTO - NOTNLM
OT  - Bayesian parameter estimation
OT  - Biodistribution
OT  - Nanobiomaterials (NBMs)
OT  - Physiologically based pharmacokinetic modeling
COIS- The authors declare no competing interests.
EDAT- 2022/05/14 06:00
MHDA- 2022/08/11 06:00
PMCR- 2022/05/12
CRDT- 2022/05/13 13:42
PHST- 2022/03/29 00:00 [accepted]
PHST- 2022/05/14 06:00 [pubmed]
PHST- 2022/08/11 06:00 [medline]
PHST- 2022/05/13 13:42 [entrez]
PHST- 2022/05/12 00:00 [pmc-release]
AID - 10.1007/s13346-022-01159-w [pii]
AID - 1159 [pii]
AID - 10.1007/s13346-022-01159-w [doi]
PST - ppublish
SO  - Drug Deliv Transl Res. 2022 Sep;12(9):2132-2144. doi: 10.1007/s13346-022-01159-w. 
      Epub 2022 May 12.